MedTrace Logo

A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer

NCT00512681 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2009-09-18

No results posted yet for this study

Summary

Patients will be treated with irinotecan (150mg/m2) followed by oxaliplatin (85mg/m2)on day 1 and S-1(80mg/m2/day) from day 1 to 14 every 3 weeks. Patients will receive up to a planned treatment of maximum 12 cycles of chemotherapy. Response assessement will be performed every 2 cycles of chemotherapy.

Conditions

  • Stomach Neoplasms

Interventions

DRUG

Irinotecan, Oxaliplatin, TS-1

* S-1 40 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning) * Irinotecan 150 mg/m2 mixed in d5w 500 ml iv over 90-min on days 1 * Oxaliplatin 85 mg/m2 mixed in d5w 250 ml iv over 2-h on days 1

Sponsors & Collaborators

  • National Cancer Center, Korea

    lead OTHER_GOV

Principal Investigators

  • Sook Ryun Park, M.D. · National Cancer Center, Korea

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00512681 on ClinicalTrials.gov